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Cathepsins have been shown to participate in dissolution and
remodelling of connective tissue and basement membranes in the
processes of tumour growth, invasion and metastasis (Sloane et
al, 1994; Kos and Lah, 1998). Increased levels of Cats B and L in
tumours and some extracellular fluids are associated with shorter
disease-free and overall survival periods and may serve as prog-
nostic factors for cancer patients (Kos and Lah, 1998). The role of
another cysteine proteinase, Cat S in tumour progression is less
understood. In contrast to Cats B and L, which are active
at acidic pH, Cat S retains most of its enzymatic activity at
pH 7.0–7.5. Another distinct feature is the substantial elastolytic
activity it exhibits at neutral pH (Chapman et al, 1997). 
Cat S exhibits restricted tissue expression and is present in
higher amounts in lymph nodes (Turens ˇek et al, 1975), spleen and
antigen-presenting cells (APCs), including macrophages, dendritic
cells and B lymphocytes (Shi et al, 1994; Morton et al, 1995). Its
expression was found to be induced by cytokines, such as inter-
feron γ and interleukin 1β (Chapman et al, 1997). 
Cat S activity appears to be essential in the MHC class II
antigen presentation pathway. It specifically degrades the invariant
chain (Ii), a MHC class II chaperone, prior to its removal from the
MHC class II peptide-binding cleft. This facilitates the loading of
antigenic peptides to MHC class II αβ -dimers and subsequent
transportation of the complex to the cell surface to initiate MHC
class II restricted CD4+ T-cell recognition (Chapman et al, 1997;
Pierre and Mellman, 1998). Besides participation in the immune
response some other specific functions, associated with high elas-
tolytic activity of Cat S have been proposed. For example, Cat S
has been suggested to promote motility of the cilia of conducting
airway cells in the lung (Chapman et al, 1997). Additionally, it was
found to participate in vascular matrix remodelling and in the
formation of the atherosclerotic intima (Sukhova et al, 1998). In
rat, Cat S is expressed in thyroid tissue, where a role in processing
thyroglobulin and release of thyroid hormone has been proposed
(Petancheska and Devi, 1992). Increased expression of Cat S has
also been associated with the pathogenesis of Alzheimer disease
(Lemere et al, 1995). 
The aim of the present study was to evaluate the role this
enzyme might have in the progression of lung cancer. For this
purpose a quantitative method for measuring the level of Cat S in
tissue extracts and sera of lung cancer patients was developed and
the levels have been tested for their relationship to clinical
features, considering especially the correlation with the survival
rate for cancer patients. Additionally, the cell types, expressing Cat
S in tumours, lung parenchyma and lymph nodes, have been eval-
uated by IHA. 
MATERIALS, METHODS AND PATIENTS 
Antigen, antibodies 
Human pro-Cat S was produced in E. coli using an inducible T7-
based expression system (Kopitar et al, 1996) and autocatalytically
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excess of cysteine and catalytic amounts of dextran sulfate. Active
Cat S was used to immunise mice and as a standard for assay cali-
bration curves. 
Monoclonal antibodies (MAbs) (Krka, d.d., Ljubljana,
Slovenia) used in ELISA, IHA and Western blots were prepared
from mouse hybridoma cell lines (Schweiger et al, 1997;
Zavas ˇnik-Bergant et al, 2001). The cell culture supernatants were
purified by affinity chromatography on protein A-Sepharose as
recommended by the producer (Pharmacia, Uppsala, Sweden).
Antibody-containing fractions were pooled, dialysed against PBS,
pH 7.2, and concentrated to at least 1 mg ml–1 by ultrafiltration.
Murine MAb was conjugated to horseradish peroxidase (HRP,
Type IV, Sigma, St Louis, USA) using the 2-step glutaraldehyde
method (Avrameas et al, 1978). 
Western blot 
Proteins were first separated by SDS-PAGE on 8–25% poly-
acrylamide gels (Pharmacia) using a PhastSystem apparatus and
procedure (Pharmacia). After electrophoresis the proteins were
transferred to a nitrocellulose membrane (Millipore, Bedford,
USA) by passive diffusion. The membrane was first soaked in
PBS, + 0.5% Tween 20, pH 7.2 to block non-specific binding and
incubated subsequently with primary MAbs, raised against human
Cat S. After washing, the membrane was incubated with 1/1000
diluted goat anti-mouse IgG conjugated to HRP (Dianova,
Hamburg, Germany). Detection was performed using 0.05% 3,3′ -
diaminobenzidine tetrahydrochloride (DAB, Sigma) and 0.09%
H2O2 in 0.05M Tris-HCl buffer, pH 7.5. 
ELISA 
The combination of 2B4 MAb and 1E3 MAb (Krka, d.d.,
Ljubljana, Slovenia) was used to optimise sandwich ELISA. Both
antibodies recognise mature and pro-forms of Cat S. Microtitre
plates were coated with 10 µ gm l –1 of 2B4 MAb in 0.01 M
carbonate/bicarbonate buffer, pH 9.4 at 4˚C. After blocking (2%
BSA-PBS, 150 µ l well–1), the samples or Cat S standards were
added (100 µ l well–1). After 2 h of incubation the wells were
washed and filled with 1E3 MAb conjugated with HRP. After a
further 2 h incubation at 37˚C 200 µ g well–1 of peroxidase
substrate 3,3′ ,5,5′ -tetramethylbenzidine (TMB, Sigma) 0.012%
H2O2, was added. After 15 min the reaction was stopped by adding
50 µ l of 2 M H2SO4. The amount of degraded substrate, as a
measure of bound immunocomplexed Cat S, was determined by
absorbance at 450 nm, and the concentration of Cat S calculated
from the calibration curve. 
IHA of Cat S in tumours, lymph nodes and parenchyma
of the lung 
Sections (3–5 µ m) from formalin-fixed, paraffin-embedded
tissues were used for immunohistochemical analysis (Hsu et al,
1981; Kayser and Gabius, 1997). Tissue sections were deparaf-
finised by xylene (2 × 5 min) and rehydrated through alcohol 99%
(2 × 5 min), 96% (1 × 2 min), 70% (1 × 2 min), 50% (1 × 2 min),
to phosphate-buffered saline (PBS), pH 7.4 (3 × 3 min). Tissue
sections were incubated with 0.1% trypsin in PBS, pH 7.4,
containing 20 mM CaCl2, at 37˚C for 30 min. They were then
washed in distilled H2O (1 × 1 min) and equilibrated in PBS
(1 × 5 min). After blocking (i) endogenous peroxidase with 3%
methanolic hydrogen peroxide for 15 min, and (ii) non-specific
binding sites with 5% normal goat serum in PBS for 30 min at
25˚C, tissue sections were rinsed in PBS (3 × 3 min) and incubated
with a monoclonal anti-human Cat S antibody (clones 2B4 and
1E3, Krka, d.d.) diluted to 8 µ g ml–1 in PBS containing 5% normal
goat serum in a humid chamber at 25˚C overnight. After washing
in PBS (3 × 3 min), detection was performed by using the highly
sensitive CSA-system (DAKO GmbH, Hamburg, Germany).
Briefly, tissue sections were incubated with biotinylated rabbit
anti-mouse Ig antibodies in 0.05 M Tris-HCl, pH 7.6 containing
5% normal goat serum. This procedure was followed by sequential
15-minute incubations with streptavidin–biotin–peroxidase com-
plex, biotinylated thyramin–peroxidase complex and streptavidin
coupled to peroxidase. After each step tissue sections were washed
in PBS (2 × 5 min). Peroxidase activity was developed for 5 min
with DAB (0.3 mg ml–1 in 0.05 M Tris-HCl buffer, pH 7.6),
including 0.2% hydrogen peroxide. The reaction was stopped by
washing the tissue sections in distilled water for 5 min. Finally,
tissue sections were lightly counterstained with 5% Harris’s
haematoxylin, dehydrated and mounted. 
The following control assays were performed: (i) pre-adsorption
of the antigen with the antibody in a 1:3 molar ratio. Cat S had
been inactivated in Tris-HCl buffer, pH 8.2 at 37˚C for 30 min
prior incubation with the antibody (Bromme et al, 1989), (ii) incu-
bation as in the assay, omitting the primary antibody; (iii) incuba-
tion omitting secondary antibody, (iiii). All control assays were
performed on 2 parallel sections. Tissue sections were inspected
by the pathologist of the Thoraxklinik in Heidelberg, Germany
(KK), classified into 2 groups and considered positive when > 5%
of stained cells (tumour cells, histiocytes, lymphocytes) were
present. 
Patients, samples 
Matched pairs of tumour and adjacent non-cancerous (parenchyma)
lung tissue were obtained from 73 patients treated by surgery at the
Thoraxhospital Heidelberg-Rohrbach (Germany). 62 were primary
non-small-cell lung cancer (NSCLC) tumours and 11 secondary
tumours. For 24 patients from this group tumour cell infiltrated
and non-infiltrated lymph nodes were also obtained. Tissue
cytosols were prepared and protein concentration determined as
described (Werle et al, 1995). 
Serum samples were obtained from 148 patients with malignant
lung tumours. Sera from 49 patients (33%) were collected before
therapy whereas from the rest of the lung cancer patients (n = 99)
sera were collected after therapy, all in the year 1997. Out of 148
patients with malignant tumours 57 were adenocarcinoma, 57
small-cell lung cancer (SCLC) and 34 squamous cell type carci-
noma. SCLC patients were treated by chemotherapy whereas non-
small-cell lung carcinoma (NSCLC) patients were treated by
surgery followed by chemotherapy and/or radiation therapy
depending on the stage of the tumour (Manegold and Drings,
1998; Schraube et al, 1998). 
A control group of sera was collected from 40 healthy donors
(Kos et al, 1998), matched for gender and age to the patient’s
population. In all cases the blood (5 ml) was clotted at 4–8˚C,
centrifuged at 3000 rpm and sera stored at –70˚C until analysed. 
Tissue sections for IHA were prepared from 26 NSCLC
tumours (9 adenocarcinoma, 6 squamous cell carcinoma, 6 large
cell carcinoma, 5 carcinoids), 7 SCLC tumours, 3 secondary
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lymph nodes. 
Statistical analysis 
For descriptive statistics, SPSS PC software was used (Release
6.0, SPSS Inc, Chicago, IL). For comparing the data of matched
pairs of tumour and lung tissue, Wilcoxon’s rank test was applied.
Differences in Cat S levels (tissue and serum) between various
groups of patients and controls were tested by Mann–Whitney and
Kruskal–Wallis test. Univariate analysis of survival probability
was performed by Kaplan–Meier analysis (Kaplan and Meier,
1958), using the log-rank test for determining statistical signifi-
cance between survival curves (Release 6.0, SPSS Inc, Chicago,
IL; PC-Statistics, TOPSOFT, Hannover, Germany). Critlevel
program (Abel et al, 1984) was used for separating variables into
low and high groups. In all tests, 2-sided P values below 5% were
considered significant. 
RESULTS 
Antibody specificity 
MAbs used in ELISA and IHA were tested for specificity by
Western blots. As evident from Figure 1, 1E3 and 2B4 MAbs
reacted with the mature (28 kDa) and pro-form (36 kDa) of recom-
binant human Cat S. Pretreatment of both MAbs with the antigen
in 1:1 to 1:3 molar ratio resulted in significant decrease of the
signal. In tissue cytosols of lung tumours and lymph nodes
predominantly the mature form of Cat S was detected (results not
shown). MAbs did not react with the related human cathepsins B,
H and L. 
Cat S protein levels in tissue cytosols and sera,
determined by ELISA 
A working range of 2–62 ng ml–1 and a detection limit, defined as
the concentration corresponding to the mean absorbance of 10
replicates of zero standards plus 3SDs of 0.8 ng ml–1, were deter-
mined from the calibration curve (Figure 2). The intra-assay coef-
ficient of variance (CV), determined by measuring 12 replicates
each of low, middle and high controls, varied from 11.5% to 3.8%.
Inter-assay precision, determined by evaluating 3 controls in
quadruplicate in 10 separate assays, ranged from CV 7.3% to
4.3%. To test the accuracy of ELISA, different amounts of recom-
binant human Cat S were added to known amounts of Cat S in
serum and tissue cytosol samples. Recovery levels were deter-
mined by comparing the expected vs observed concentrations and
ranged from 85.2% to 116.0% (Figure 2). Additionally, tissue
cytosols and sera were serially diluted to the levels encompassing
the range of the assay. The linearity of the response was evaluated
by comparing the measured values with the calibration values. The
dilution curves for sera and tissue cytosols were linear between
1 : 4 and 1 : 60 (Figure 2). The optimal dilution of samples was
defined from the linear range of dilution curves. For sera it ranged
from 1/4 to 1/30, for tissue extracts from 1/6 to 1/60. 
The median levels of Cat S in tumours and adjacent lung tissues
of 62 NSCLC patients are shown in Table 1. The Cat S level is
approximately 2 times higher in tumour than control lung tissue.
No significant difference was found between adenocarcinomas
and squamous cell carcinomas, whereas in secondary tumours the
Cat S level was significantly lower than in primary tumours (P =
0.01). Additionally, Cat S levels were not associated with tumour
grade or TNM status. In non-invaded lymph node tissue obtained
from the same patients the median level of Cat S was 16.6 ng mg–1
of total protein (range 5.4–77.2) whereas in lymph nodes invaded
by tumour cells, it was significantly lower-7.5 ng mg–1 (range
2.0–84.0, P < 0.001). Mean values ± 2 SEM are shown in Figure 3. 
In sera the median levels of Cat S were 14.2 ng ml–1 (range
9.1–24.0) for healthy controls and 13.1 ng ml–1 (range 8.0–28.5)
for patients with malignant disease. For both groups no association
with age or gender has been observed. The difference was neither
Cathepsin S in lung cancer 1195
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Figure 1 Western blot of partially activated pro-Cat S developed with anti-
Cat S 2B4 and 1E3 MAbs. a: developed with 2B4 MAb, pretreated with the
antigen (1 : 2 molar ratio); b: as (a) but without pretreatment; c: developed
with 1E3 MAb, pretreated with antigen (1 : 2 molar ratio); d: as (c) but without
pretreatment; e: molecular mass standards 
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Figure 2 Calibration curve for Cat S in ELISA. Insertion right: dilution
curves of 4 serum samples (....) and 3 tissue cytosols (——) of normal lung.
(—) Standard curve. Insertion left: Analytical recovery: observed vs.
expected concentration of added Cat S in serum and tissue cytosol samples significant between the control group and patients with malignant
disease nor between groups with different histologies or between
pre-therapy and post-therapy sera. 
IHA 
Immunohistochemical staining of lung parenchyma, regional
lymph nodes and lung tumours of different origin is shown in
Figure 4. The location of Cat S in an alveolus is seen in Figure 4A,
B, where a brown staining reaction is visible in alveolar type II
cells and macrophages. The enzyme shows a lysosomal distribu-
tion over the cytoplasm. In addition, we observed different
staining intensity of Cat S in macrophages as well as in alveolar
type II cells. Immunoreactive Cat S was not found in alveolar type
I cells. Furthermore, Cat S was present in a high concentration also
in bronchial epithelial cells, showing either a lysosomal distribu-
tion or a more restricted localisation in the basal proliferating zone
of the epithelium. 
The analysis of infiltrated regional lymph node tissue revealed a
strong staining of Cat S in lymphocytes whereas in non-infiltrated
tissue Cat S was stained in lymphocytes and histiocytes, most
likely macrophages. Cat S can also be detected in lung tumours,
independently of their origin. We found a positive reaction in
adenocarcinomas, squamous cell carcinomas and small cell carci-
nomas. Remarkably, a weak-positive reaction at the sites of inter-
action between tumour cells of the small cell carcinoma and the
extracellular matrix of the alveoli could be observed. Correlation
of Cat S staining (positive vs. negative) with clinico-pathological
parameters of NSCLC patients is shown in Table 2. No significant
correlation between Cat S level and grading or tumour stage has
been observed. Table 3 shows IHA of Cat S in lung tumours,
secondary tumours, benign lung tissue and infiltrated and non-
infiltrated lymph nodes with regard to staining intensity in tumour
cells, histiocytes and lymphocytes. 
Survival analysis 
Cat S levels in tumour tissue cytosols and adjacent control lung
parenchyma from 60 patients with NSCLC were included in
univariate survival analysis. Median follow-up of the observed
tumour patients was 3.0 years (25th percentile: 1.09 years). Cut-
off values of 5.0 ng mg–1 for tumour tissue and 0.5 ng mg–1 for
lung tissue have been optimised using the Critlevel program (Abel
et al, 1984). In both groups, patients with the levels above the cut-
off values experienced significantly better survival probability
than the patients with lower Cat S levels (P = 0.025 – tumours;
1196 J Kos et al 
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Table 1 Cat S levels in tumour and lung tissue cytosols 
Cat S (ng mg–1 protein) 
n Tumour median (5%, 95%) Lung median (5%, 95%) P value 
Non-small-cell lung cancer 62 4.8 2.1 < 0.0001 
(0.6, 29.2) (0.4, 7.6)
Adenocarcinomas 31 4.9 1.9 < 0.001 
(0.5, 19.8) (0.4, 7.7)
Squamous cell carcinomas 31 4.2 2.6 < 0.01 
(0.6, 162) (0.4, 7.7)
Secondary tumours 11 3.0 0.7 < 0.01 
(0.5, 47.6) (0.3, 6.2)
Well/moderately differentiated 20 3.2
(G1/G2) (0.5, 38.8)
Poorly differentiated (G3) 57 4.9
(0.5, 31.7)
pTNM I 15 5.0
(0.5, 29.9)
pTNM II 11 4.9
(0.9, 162)
pTNM IIIa 22 5.2
(0.7, 11.9)
pTNM IIIb 12 3.8
(0.4, 13.2)
pTNM IV 5 5.1
(1.4, 201.6)
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Figure 3 Cat S levels in tumours, control lung tissue and lymph nodes of
patients with lung cancer (n = 29). Error bars represent 2 SEM P = 0.02 – parenchyma) (Figure 5). In addition, survival curves are
significantly separated in the first 2 years of follow-up. 
DISCUSSION 
Lysosomal cysteine proteinases are known to mediate intracellular
protein turnover, regulating the lifetime of proteins critical for
normal cell function. They are also involved in specific processing
steps for smaller peptides, pro-hormones and pro-enzymes
(Uchiyama et al, 1994). Some cysteine proteinases such as Cats B,
L and H, are expressed in almost all cells, suggesting a house-
keeping function in protein turnover, whereas the expression of
others, e.g. Cats S, K and V is restricted to particular tissues and
cells, indicating more specific roles in cell physiology. 
Cat S is distinguished from the other members of papain super-
family by its high stability at neutral pH and expression, restricted
to lymphatic tissues and antigen-presenting cells (Wiederanders
et al, 1991; Brömme et al, 1994). Some of the specific properties
are consistent with subtle structural differences found in the active
site of Cat S by crystal structure analysis (McGrath et al, 1998;
Gunc ˇar et al, 1999). Due to the localisation in lymphatic tissues
and cells it was suggested that Cat S is involved in modulating the
immune response (Chapman et al, 1997; Kirschke et al, 1998). Its
specific role in processing the invariant chain (Ii) designates this
enzyme as a potentially useful therapeutic target in diseases asso-
ciated with a hyperimmune response, such as asthma, hypersensi-
tive pneumonitis and autoimmune disorders (Chapman et al,
1997). Since there is an increasing body of evidence that impaired
antigen-processing might also be associated with malignant trans-
formation and escape of tumour cells from recognition by T cells
(Seliger et al, 2000), the knowledge on tumour Cat S could help to
characterise the molecular mechanisms regulating presentation of
tumour-associated antigens (TAA). 
On the other hand, Cat S expresses broad endopeptidase activity
at neutral pH, so one may expect it to play a role in extracellular
tissue remodelling associated with tumour invasion and metas-
tasis. Indeed, in our previous study we found that the increased
activity of Cat S is associated with lung tumours (Werle et al,
1999). Quantitative determination of the protein levels of Cat S
should provide additional insight into the role of this enzyme in
malignant processes. For this reason we have developed a quanti-
tative ELISA, using 2 monoclonal antibodies recognising distinct
epitopes on Cat S molecule. Both MAbs, 1E3 and 2B4, used in
the assay recognize the pro-form (36 kDa) and the mature form (28
Cathepsin S in lung cancer 1197
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Figure 4 IHA of Cat S in lung parenchyma. (A) An alveolus consisting of alveolar type I cells, alveolar type II cells and macrophages. Alveolar type I cells did
not stain (white arrow), while alveolar type II cells and macrophages show a granular cytoplasmic staining pattern (black arrow). (B) Bronchial epithelial cells
show a lysosomal distribution for Cat S and a positive reaction in the basal proliferating zone of the epithelium as well (black arrow). In regional lymph nodes,
(C) and (E) show the typical sinusoid structure of a lymph node containing different types of lymphocytes (black arrow). Lymphocytes and histiocytes, most
probably macrophages, stained strongly positive. (D) Shows the corresponding negative control. F–H show lung tumours of different histologies.
(F) Adenocarcinoma located around a blood vessel. The cytoplasm of tumour cells stained positive (black arrow). Erythrocytes and connective tissue clearly 
did not stain (white arrow). (G) A weak positive reaction could be observed at sites of interaction between tumour cells of a small cell carcinoma and the
extracellular matrix of the alveoli, but also within the tumour (small black arrows). Lymphocytes did not stain. (H) Squamous cell carcinoma surrounded with
connective tissue. Tumour cells show a faint positive reaction (black arrows) 1198 J Kos et al 
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Table 3 Immunohistochemical analysis of Cat S in lung tumours and infiltrated lymph nodes 
Tumour cells Histiocytes Lymphocytes 
n yes / no yes / no yes / no 
Malignant lung tissue 36
Non-small-cell lung cancer 26 16 10 7 19 6 20 
Adenocarcinomas 9 6 3 2 7 1 8 
Squamous cell carcinomas 6 2 4 1 5 1 5 
Large cell carcinoma 6 4 2 2 4 2 4 
Carcinoid 5 4 1 2 3 2 3 
Small cell lung cancer 7 5 2 1 6 2 5 
Secondary tumoursa 31 21 2 0 3  
Benign lung tissueb 63 3 1 5  
Lymph node tissue 
Infiltrated 4 2 2 0 4 2 2 
Non-infiltrated 6 2 4 2 4 
aTumours of other organs to the lung. 
bFocal reaction in alveolar duct cells. 
0 1 2 34 5 67 8
0 1 2 34 5 67 8
Survival time (years)
Survival time (years)
25/43
11/29
Lung tumour tissue P < 0.025
Cat S > 5.0 (ng mg–1)
Cat S > 5.0 (ng mg–1)
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.1
0.2
Lung parenchyma P < 0.002
9/12
27/58
Cat S > 0.5 (ng mg–1)
Cat S > 0.5 (ng mg–1)
Figure 5 Prognostic significance of Cat S levels in parenchyma (A) and tumours (B) of lung cancer patients. Patients with Cat S levels below cut-off value had
a significantly shorter overall survival (  deceased patients, uncensored data; + still living patients, censored data) than patients with Cat S levels above cut-off
value (  deceased patients, uncensored data;+ still living patients, censored data) Cathepsin S in lung cancer 1199
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kDa) of recombinant and natural antigen as shown by Western blot
analysis. The new ELISA enables reliable and accurate quantifica-
tion of Cat S in tissue cytosols and sera of lung cancer patients. 
The levels of Cat S found in lung tissue and lymph nodes agree
well with previous reports on the higher expression of this enzyme
in lymphatic tissues. Its mean level was 5 times higher in lymph
nodes than in lung parenchyma. The levels of Cat S in tumour
tissues were found to be higher than those in control parenchyma
from the same patients, revealing a possible role for this enzyme in
tumour growth and progression. However, serum levels of Cat S
were not significantly changed from control levels in patients with
malignant disease. Although in our previous report we showed
also an increased enzymatic activity of Cat S in lung tumours
(Werle et al, 1999), it seems that Cat S is not involved in tumour
development and progression to the same extent as are the related
cysteine proteinases Cats B and L. These are significantly over-
expressed in lung tumours, released to the extracellular space and
participate in degradation of extracellular matrix proteins (Kos and
Lah, 1998). The lack of any correlation of Cat S activity or protein
levels with clinical and pathological parameters indicating tumour
progression, is consistent with the latter conclusion. In IHA, a
positive immunostaining reaction in tumour tissue was observed
not only in tumour cells but also in epithelial cells, histiocytes and
infiltrated lymphocytes, which may all significantly contribute to
the higher overall Cat S protein content and activity. In normal
lung tissue a significant staining reaction was observed in alveolar
type II cells and macrophages and in bronchial epithelial cells. Its
localisation in the basal proliferating zone of the epithelium is
consistent with the proposed role of this enzyme in the motility of
cilia of conducting lung airway cells (Chapman et al, 1997). 
Cat S protein levels in infiltrated lymph nodes revealed a
significant decrease compared with non-infiltrated lymph nodes.
By contrast, the Cat B level was the highest in infiltrated lymph
nodes, as shown in our previous study (Werle et al, 2000). From
IHA it is evident that Cat S staining in regional lymph nodes is
the most extensive in lymphocytes and histiocytes whereas Cat B
was predominantly present in tumour cells, partially in histio-
cytes and absent in lymphocytes. Lower levels of Cat S could be
related to the lower expression in affected lymphoid tissue or to
the lower number of lymphatic cells. A tumour-directed immune
response usually results in enlargement of lymph nodes as a
consequence of the increase of the number of lymphoid cells
(Lores et al, 1998). However, this vigorous process is limited to
the early growth of tumours and is soon down-regulated, permit-
ting progressive tumour growth and proliferation (Barna and
Deodhar, 1975). 
There is growing evidence that CD4+ T cells play a central role
in initiating and effecting antitumour immunity. TAA can be
presented to CD4+ T cells by professional APCs cells as well as by
MHC class II+ tumour cells. For direct antigen presentation these
tumour cells must leave primary tumour site and enter the
lymphatic system and draining lymph nodes. The expression of
MHC class II molecules in tumour cells varies among different
tumour types and has been associated with both, poor and good
prognosis of cancer patients (Seliger et al, 2000). The expression
of other proteins involved in class II antigen presentation and their
relation to the course of disease have not been systematically
analysed. We have no direct evidence that Cat S is involved in
regulation of antitumour immunity, however, we may speculate
that its high expression in potential APCs could be beneficial for
cancer patients. The latter is consistent with the survival analysis
of Cat S in lung cancer patients. It confirmed different pattern for
Cat S compared with other cathepsins. Numerous clinical studies
on different cancer types have provided evidence that patients with
high levels of Cats B and L show higher risk of relapse or death
(Kos et al, 1998). In contrast, in this study patients with high levels
of Cat S experienced significantly better survival probability than
those with low levels of Cat S. Prognostic value was defined not
only for tumour samples but, even more significantly, for control
lung parenchyma. The latter further indicates that increased
expression of Cat S is not linked just to the tumour cells and their
proliferation and invasion but merely reflects defence mechanisms
leading to the regression of malignant disease and better outcome
of cancer patients. 
In conclusion, the results of our study reveal an increased expres-
sion of Cat S in lung tumours. Its role, however, does not seem to be
pivotal in remodelling extracellular matrix proteins, resulting in
tumour growth, proliferation and metastasis. Its high expression in
lymphocytes and histiocytes, decreased levels in infiltrated lymph
nodes and a correlation of low levels with poor patient survival,
could be related to the modulation of antigen presentation and
consequently the response to tumour antigens in cancer patients. 
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Table 2 Correlation of Cat S staining in tumour tissue sections with clinico-
pathological parameters 
n Negative Positive 
G1/2 8 5 3 
G3 18 9 9 
pT1 3 1 2 
pT2 16 10 6 
pT3 4 3 1 
pT4 3 2 1 
pN0 15 10 5 
pN1 4 2 2 
pN3 0 0 0 
pTNM I 8 5 3 
pTNM II 2 1 1 
pTNM IIIa 9 6 3 
pTNM IIIb 1 1 0 
pTNM IV 6 3 3 
Tissue sections were considered positive when more than 5% of cells were
stained. The tumour disease stage was classified according to the
international staging system (Hermanek and Sobin, 1987). 1200 J Kos et al 
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